



(51) International Patent Classification:

C07K 7/52 (2006.01) *A61K* 38/12 (2006.01)
C07K 7/56 (2006.01) *G01N* 33/68 (2006.01)

(21) International Application Number:

PCT/US2015/054407

(22) International Filing Date:

7 October 2015 (07.10.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/062,240 10 October 2014 (10.10.2014) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: **SUN, Li-Qiang**; c/o Bristol-Myers Squibb
Company, 5 Research Parkway, Wallingford, Connecticut
06492 (US). **ZHAO, Qian**; c/o Bristol-Myers Squibb
Company, 5 Research Parkway, Wallingford, Connecticut
06492 (US). **MULL, Eric**; c/o Bristol-Myers Squibb Com-
pany, 5 Research Parkway, Wallingford, Connecticut
06492 (US). **GILLIS, Eric P.**; c/o Bristol-Myers Squibb
Company, 5 Research Parkway, Wallingford, Connecticut
06492 (US). **SCOLA, Paul Michael**; c/o Bristol-Myers
Squibb Company, 5 Research Parkway, Wallingford, Con-
necticut 06492 (US).

(74) Agents: **MINGO, Pamela A.** et al.; Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: IMMUNOMODULATORS

(57) Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.



WO 2016/057624 A1